Search Result

Pathways Recommended:	Anti-infection

Results for "

MRSA infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminoacyl-tRNA Synthetase (4) Amyloid-β (5) Antibiotic (24) Apoptosis (1) Autophagy (1) Bacterial (62) Dihydrofolate reductase (DHFR) (2) DNA/RNA Synthesis (3) Fungal (8) HIV (1) Influenza Virus (1) PPAR (1) Proteasome (5) Pyruvate Kinase (1) Reactive Oxygen Species (ROS) (5) Reference Standards (7) SARS-CoV (1) Toll-like Receptor (TLR) (2) Topoisomerase (3)
By Research Areas:	Cancer (8) Endocrinology (9) Infection (65) Inflammation/Immunology (8) Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14737

Ceftaroline fosamil 2 Publications Verification TAK-599; PPI0903	Bacterial Antibiotic	Infection
Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .

HY-14784

Bederocin REP8839	Bacterial	Infection
Bederocin (REP8839) is a Methionyl-tRNA synthetase inhibitor. Bederocin can be used in research of bacterial infection, including S. aureus and MRSA .

HY-119123A

Voxvoganan trihydrochloride LTX-109 trihydrochloride	Fungal Bacterial	Infection
Voxvoganan (LTX-109) trihydrochloride, a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan trihydrochloride can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA .

HY-14737R

Ceftaroline fosamil (Standard) TAK-599 (Standard); PPI0903 (Standard)	Reference Standards Bacterial Antibiotic	Infection
Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].

HY-14738

Ceftaroline fosamil (inner) TAK-599 free acid; PPI0903 free acid	Bacterial Antibiotic	Infection
Ceftaroline fosamil (inner) (TAK-599 free acid), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil (inner) can be used for the research of MRSA infection .

HY-119123

Voxvoganan LTX-109	Fungal Bacterial	Infection
Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA .

HY-P5545

Lynronne-1	Bacterial	Infection
Lynronne-1 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 8-32 μg/mL for methicillin-resistant MRSA strains). Lynronne-1 reduces the bacterial load in MRSA infected wound murine model. Lynronne-1 is also effective against P. aeruginosa infection .

HY-P5547

Lynronne-3	Bacterial	Infection
Lynronne-3 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 32-128 μg/mL for methicillin-resistant MRSA strains). Lynronne-3 is also effective against P. aeruginosa infection

HY-P5546

Lynronne-2	Bacterial	Infection
Lynronne-2 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 32-256 μg/mL for methicillin-resistant MRSA strains). Lynronne-2 is also effective against P. aeruginosa infection

HY-157482

EBP-59	Bacterial	Infection
EBP-59 is a bacterial inhibitor with antibiofilm activity against Gram-positive bacteria. EBP-59 is effective against Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus). EBP-59 can be used to study bacterial infections .

HY-N9690

Longistyline A Longistylin A	Bacterial	Infection Neurological Disease
Longistyline A (Longistylin A) is a natural stilbene, it can be isolated from leaves of Cajanus cajan. Longistyline A shows antimicrobial activity against *MRSA* with an MIC value of 1.56 μg/mL. Longistyline A shows neuroprotective effects, it can be used for the research of infection and nerve diseases .

HY-112959

Telavancin TD-6424	Antibiotic Bacterial	Infection
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .

HY-14737A

Ceftaroline fosamil hydrate 2 Publications Verification TAK-599 hydrate; PPI0903 hydrate	Antibiotic Bacterial	Infection
Ceftaroline fosamil hydrate is a potent cephalosporin antibiotic. Ceftaroline fosamil hydrateshows broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative organisms. Ceftaroline fosamil hydrate has anti-infective activity, and can be used for the research of complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) .

HY-174985

Anti-MRSA agent 32	Bacterial	Infection
Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC₅₀ value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .

HY-163984

Antibacterial agent 240	Bacterial	Infection
Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) *MRSA* strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection .

HY-173225

MRSA/VRE-IN-1	Bacterial	Infection
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .

HY-N3515

Multicaulisin	Bacterial	Infection
Multicaulisin, a new Diels-Alder type adduct from Morus multicaulis roots, potently effects against Staphylococcus aureus (MRSA) isolates. Multicaulisin is an antibacterial agent and has the potential for MRSA infections research .

HY-139679

Antibacterial agent 28	Bacterial	Infection
Antibacterial agent 28 is a potential antibacterial candidate for combating MRSA infections (MICs = 0.5–2 μg/mL).

HY-Z8025

Deprodone	Bacterial	Infection Inflammation/Immunology
Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders .

HY-172826

Anti-MRSA agent 26	Bacterial	Infection
Anti-MRSA agent 26 is a potent *anti-MRSA* agent with MIC <0.015 μg/mL. Anti-MRSA agent 26 has superior activity against a broad range of Gram-positive pathogens and shows no cytotoxicity in three mammalian cell lines (Caco-2, DU-145 and MDCKII MDR1 cells) at 10 μM. Anti-MRSA agent 26 has a robust TAP pharmacophore and an excellent antibacterial activity in Staphylococcus aureus skin infection mice model .

HY-173318

Anti-MRSA agent 25	Bacterial	Infection
Anti-MRSA agent 25 (Compound 10c) is an antibacterial agent with a MIC of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 25 exerts its antibacterial activity by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acids), acting on the cell membrane (causing depolarization, increasing permeability, and disrupting integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 is expected to be used in the research of the anti-infection field .

HY-173478

OSUAB-0284	Topoisomerase Bacterial Antibiotic	Infection
OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .

HY-P10345

OP-145	Bacterial	Infection
OP-145, an cathelicidin LL-37 derivative, is an antimicrobial peptide, and shows antibacterial activity against several MRSA strains. OP-145 can be used for research of chronic suppurative otitis media .

HY-N7111

Sultamicillin tosylate Sultamicillin (tosilate)	Bacterial Antibiotic	Infection
Sultamicillin tosylate is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N7111R

Sultamicillin tosylate (Standard) Sultamicillin (tosilate) (Standard)	Reference Standards Bacterial Antibiotic	Infection
Sultamicillin (tosylate) (Standard) is the analytical standard of Sultamicillin (tosylate). This product is intended for research and analytical applications. Sultamicillin tosylate is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N7115R

Sultamicillin (Standard)	Reference Standards Bacterial Antibiotic	Infection
Sultamicillin (Standard) is the analytical standard of Sultamicillin. This product is intended for research and analytical applications. Sultamicillin is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N7115

Sultamicillin	Bacterial Antibiotic	Infection
Sultamicillin is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N15451

Deoxytopsentin	Pyruvate Kinase	Infection
Deoxytopsentin is a compound that can be found in marine sponges. It is an inhibitor of pyruvate kinase (PK) in methicillin-resistant Staphylococcus aureus (MRSA), with an IC₅₀ value of 240 nM. Deoxytopsentin can be used in research in the field of anti-infection .

HY-156122

DHFR-IN-8	Dihydrofolate reductase (DHFR) Bacterial	Infection
DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC₅₀=15.6 ng/mL) in mouse models of systemic infection and thigh infection .

HY-174273

Antibacterial agent 280	Bacterial	Infection
Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .

HY-146811

HSGN-94	Bacterial	Inflammation/Immunology
HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .

HY-B0958

Mupirocin BRL-4910A; Pseudomonic acid	Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-125747

Actinomycin X2 1 Publications Verification Actinomycin V	Bacterial Antibiotic Apoptosis	Infection Cancer
Actinomycin X2 (Actinomycin V)，produced by many Streptomyces sp.，shows strong inhibition of *MRSA* with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection .

HY-W108875

Mupirocin lithium BRL-4910A lithium; Pseudomonic acid lithium	Antibiotic Bacterial Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-163700

Fabl inhibitor 1	Bacterial	Infection
Fabl inhibitor 1 (Compound (S)-n31) is an orally active and potent SaFabI inhibitor (IC₅₀ = 94.0 nM, MIC = 0.25-1 μg/mL). Fabl inhibitor 1 can be used for the research of methicillin-resistant S. aureus (MRSA) infection .

HY-172813

Vancomycin prodrug	Bacterial Antibiotic Autophagy	Infection Cancer
Vancomycin prodrug (compound 13c) is a Vancomycin (HY-B0671) prodrug. Vancomycin prodrug shows antibacterial effect with MICs of 0.78 μM, 0.78 μM, 1.56 μM for S. aureus 330041, MRSA USA 300 and MRSA 3390, respectively. Vancomycin prodrug has the ability to quickly bind to Cys-34 residue of plasma. Vancomycin prodrug exhibits a good therapeutic effect on MRSA USA300 infected mice similar to Vancomycin. Vancomycin prodrug, an albumin-binding acid-sensitive prodrug, effectively reduces Vancomycin’s nephrotoxicity while maintaining its efficacy for Gram-positive bacterial infections .

HY-B1924

Norvancomycin monohydrochloride 1 Publications Verification N-Demethylvancomycin monohydrochloride; NVCM monohydrochloride	Bacterial Antibiotic	Infection
Norvancomycin hydrochloride is a cell wall synthesis inhibitor targeting peptidoglycan precursors of Gram-positive bacteria and cannot pass the blood-brain barrier. Norvancomycin hydrochloride can competitively bind to peptidoglycan precursors, irreversibly inhibit bacterial cell wall synthesis, and exert antibacterial activity. Norvancomycin hydrochloride is mainly used in the study of Gram-positive bacterial infections, especially infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Norvancomycin hydrochloride can also be incorporated into the bionic calcium phosphate coating of titanium implants to enhance antibacterial activity and inhibit postoperative orthopedic infections .

HY-B0958R

Mupirocin (Standard) BRL-4910A (Standard); Pseudomonic acid (Standard)	Reference Standards Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin (Standard) is the analytical standard of Mupirocin (HY-B0958). This product is intended for research and analytical applications. Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-16764A

Acorafloxacin hydrochloride JNJ-Q2 hydrochloride	Bacterial	Infection Inflammation/Immunology
Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia . Acorafloxacin hydrochloride (Avarofloxacin ) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC₉₀ value . Acorafloxacin hydrochloride (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Bacterial Antibiotic	Infection
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Antibiotic HIV SARS-CoV	Infection
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-108569

nTZDpa	Antibiotic Bacterial PPAR	Infection
nTZDpa is an antibiotic. nTZDpa is a PPARG partial agonist. nTZDpa has antibacterial activity. nTZDpa is effective against growing and persistent Staphylococcus aureus by lipid bilayer disruption .

HY-16764

Avarofloxacin JNJ-Q2	Bacterial Antibiotic	Infection Inflammation/Immunology
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial agent being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia with oral activity. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC₉₀ value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .

HY-174158

Antibacterial agent 270	Bacterial	Infection
Antibacterial agent 270 (Compound 3e) is an antibacterial agent that acts on bacterial membrane components phosphatidylglycerol (PG), cardiolipin (CL), and bacterial DNA. Antibacterial agent 270 disrupts bacterial membrane structure and binds to DNA to interfere with genetic information transmission. Antibacterial agent 270 is promising for research of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) .

HY-W108875R

Mupirocin lithium (Standard) BRL-4910A lithium (Standard); Pseudomonic acid lithium (Standard)	Antibiotic Bacterial Reference Standards Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin (lithium) (Standard) is the analytical standard of Mupirocin lithium (HY-W108875). This product is intended for research and analytical applications. Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-16485

Telavancin hydrochloride TD-6424 hydrochloride	Antibiotic Bacterial	Infection
Telavancin hydrochloride is the hydrochloride form of Telavancin (HY-112959). Telavancin hydrochloride is a semisynthetic derivative of vancomycin, and exhibits antibacterial efficacy through inhibition of cell wall synthesis and disruption of cell membrane barrier function. Telavancin hydrochloride is efficient against antibiotic resistant S. aureus strains MRSA, VISA, and hVISA. Telavancin hydrochloride attenuates gram positive bacteria induced complicated skin and skin structure infections (cSSSI) .

HY-173240

IPMCL-28b	Bacterial	Infection
IPMCL-28b is an antibacterial agent targeting the bacterial cell membrane. Its minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 25923 is 1.56 μg/mL, and the MIC against methicillin-resistant Staphylococcus aureus (MRSA) is 6.25 μg/mL. IPMCL-28b is expected to be used in the research of the anti-infection field .

HY-P4204

Ranalexin	Bacterial	Infection
Ranalexin is an antimicrobial peptide. Ranalexin inhibits S. aureus, E. coli, P. aerugiaosa with MICs of 4, 32, 128 μg/mL .

HY-174323

Anti-MRSA agent 28	Bacterial DNA/RNA Synthesis	Infection
Anti-MRSA agent 28 is an antibacterial agent against multidrug resistant (MDR) gram-positive strains with MICs of 0.06-0.125 μg/mL. Anti-MRSA agent 28 can target DNA polymerase IIIC to reduce the amount of genomic DNA with the IC₅₀ of 3.80 μg/mL. Anti-MRSA agent 28 has good antibacterial activity and reduces inflammation. Anti-MRSA agent 28 can be used against gram-positive strains and infectious conditions.

HY-P1405

Pam3CSK4-Biotin Pam3Cys-Ser-(Lys)4-Biotin	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4-Biotin is biotinylated Pam3CSK4. Pam3CSK4-Biotin is a Toll-like receptor 1/2 (TLR1/2) agonist .

Cat. No.	Product Name	Type

HY-69174

1-Amino-2,5-anhydro-1-deoxy-D-mannitol

Microbial Culture

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.

Cat. No.	Product Name	Target	Research Area